NASDAQ:ELTX Elicio Therapeutics Q4 2024 Earnings Report $1.87 0.00 (0.00%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Elicio Therapeutics EPS ResultsActual EPS-$1.02Consensus EPS -$0.94Beat/MissMissed by -$0.08One Year Ago EPSN/AElicio Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AElicio Therapeutics Announcement DetailsQuarterQ4 2024Date3/31/2025TimeBefore Market OpensConference Call DateMonday, March 31, 2025Conference Call Time7:00AM ETUpcoming EarningsElicio Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Elicio Therapeutics Earnings HeadlinesElicio Therapeutics, Inc. (NASDAQ:ELTX) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 23 at 2:58 AM | americanbankingnews.comElicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from S&P Global BMI IndexSeptember 21 at 12:29 PM | marketscreener.comMWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing. | The Oxford Club (Ad)Elicio Therapeutics Sets Key 2026 Shareholder Proposal DeadlinesSeptember 14, 2026 | tipranks.comElicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment ConferenceAugust 31, 2026 | globenewswire.comElicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceAugust 24, 2026 | globenewswire.comSee More Elicio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Elicio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elicio Therapeutics and other key companies, straight to your email. Email Address About Elicio TherapeuticsElicio Therapeutics (NASDAQ:ELTX) is a clinical-stage biotechnology company developing cancer immunotherapies designed to activate and strengthen the immune system’s response to tumors. The company’s approach is based on its Amphiphile technology, which is intended to direct therapeutic agents to lymph nodes, where immune responses are initiated and expanded. Elicio’s leading program, ELI-002, is an investigational therapeutic cancer vaccine targeting common KRAS mutations. The program is being studied in patients with certain solid tumors, including pancreatic and colorectal cancers, with the goal of treating minimal residual disease and reducing the risk of recurrence. The company is also advancing additional vaccine and immunotherapy programs based on its lymph-node-targeting platform. Based in the United States, Elicio focuses on developing therapies for patients with cancer and works through clinical research and biotechnology partnerships. Its products remain investigational and are not approved for general commercial use.View Elicio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
